Key statistics
On Monday, 4D Molecular Therapeutics Inc (FDMT:NSQ) closed at 3.90, 1.43% above its 52-week low of 3.84, set on Mar 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.10 |
---|---|
High | 4.21 |
Low | 3.84 |
Bid | 3.91 |
Offer | 4.26 |
Previous close | 4.07 |
Average volume | 785.39k |
---|---|
Shares outstanding | 46.30m |
Free float | 44.42m |
P/E (TTM) | -- |
Market cap | 188.45m USD |
EPS (TTM) | -2.97 USD |
Data delayed at least 15 minutes, as of Mar 10 2025 20:00 BST.
More ▼
- 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
- 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
- 4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
- 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
- 4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
- 4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
- 4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
- 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
More ▼